Literature DB >> 16152593

Steroid hormone receptors and coregulators in endocrine-resistant and estrogen-independent breast cancer cells.

Nanna Sarvilinna1, Heli Eronen, Susanna Miettinen, Annika Vienonen, Timo Ylikomi.   

Abstract

Resistance to hormonal therapy is often a problem in the treatment of breast cancer patients. It has been suggested that resistance could be explained by altered nuclear hormone receptor or coregulator levels or inappropriately increased agonist activity of selective estrogen receptor modulator (SERM). To test these hypotheses, we have established novel MCF-7 cell line-derived in vitro models of anti-estrogen- and progestin-resistant and estrogen-independent breast cancer by long-term culture in the presence of toremifene and medroxyprogesterone acetate (MPA) and in the absence of estradiol, respectively. Using cell growth and multiprobe ribonuclease protection assays, the expression of 5 nuclear hormone receptors and 9 coregulators as well as the alterations in the cell proliferation and target gene transcription in response to hormonal treatments were studied. Progesterone receptor (PR) expression was decreased and silencing mediator for retinoid acid and thyroid hormone receptors (SMRT) and amplified in breast cancer-1 (AIB1) expression increased in anti-estrogen-resistant cells. Estrogen caused PR and ERbeta upregulation in all cell lines, but we did not observe increased agonist activity of anti-estrogen measured by regulation of these estrogen target genes. Basal ERalpha levels and estrogenic growth response were decreased and p300/CBP-associated factor (pCAF) and AIB1 upregulated by estrogen in progestin-resistant cells, but coregulator levels were unchanged. Estrogen-independent cells were still estrogen-responsive and PR, nuclear receptor corepressor (N-CoR) and SMRT expression was increased whereas steroid receptor coactivator-1 (SRC-1a) and CBP-related protein p300 (p300) expression decreased. Their growth was inhibited by toremifene, but estradiol was able to abrogate this effect, which might have interesting clinical implications concerning the use of postmenopausal hormone replacement therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16152593     DOI: 10.1002/ijc.21431

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Distinctive functions of p160 steroid receptor coactivators in proliferation of an estrogen-independent, tamoxifen-resistant breast cancer cell line.

Authors:  Sudipan Karmakar; Estrella A Foster; Julia K Blackmore; Carolyn L Smith
Journal:  Endocr Relat Cancer       Date:  2010-12-21       Impact factor: 5.678

2.  Cooperative activation of cyclin D1 and progesterone receptor gene expression by the SRC-3 coactivator and SMRT corepressor.

Authors:  Sudipan Karmakar; Tong Gao; Margaret C Pace; Steffi Oesterreich; Carolyn L Smith
Journal:  Mol Endocrinol       Date:  2010-04-14

3.  Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence.

Authors:  Carolyn L Smith; Ilenia Migliaccio; Vaishali Chaubal; Meng-Fen Wu; Margaret C Pace; Ryan Hartmaier; Shiming Jiang; Dean P Edwards; M Carolina Gutiérrez; Susan G Hilsenbeck; Steffi Oesterreich
Journal:  Breast Cancer Res Treat       Date:  2012-09-27       Impact factor: 4.872

4.  Unique roles of p160 coactivators for regulation of breast cancer cell proliferation and estrogen receptor-alpha transcriptional activity.

Authors:  Sudipan Karmakar; Estrella A Foster; Carolyn L Smith
Journal:  Endocrinology       Date:  2008-12-18       Impact factor: 4.736

5.  Estradiol and tamoxifen mediate rescue of the dominant-negative effects of estrogen response element-binding protein in vivo and in vitro.

Authors:  Hong Chen; Thomas L Clemens; Martin Hewison; John S Adams
Journal:  Endocrinology       Date:  2008-12-23       Impact factor: 4.736

6.  Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells.

Authors:  Tissa T Manavalan; Yun Teng; Lacey M Litchfield; Penn Muluhngwi; Numan Al-Rayyan; Carolyn M Klinge
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

7.  Hormonal Homologies between Canine Mammary Cancer and Human Breast Cancer in a Series of Cases.

Authors:  Paloma Jimena de Andrés; Sara Cáceres; Juan Carlos Illera; Belén Crespo; Gema Silván; Felisbina Luisa Queiroga; Maria José Illera; Maria Dolores Pérez-Alenza; Laura Peña
Journal:  Vet Sci       Date:  2022-07-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.